Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Pangaea Logistics Solutions Q1 2026 Earnings Call - TCE Premiums and Chartered-In Fleet Expansion Drive Stronger Profitability
Pangaea Logistics Solutions delivered a solid Q1 2026, with adjusted EBITDA up $10M YoY to $25.2M, driven by TCE rates averaging 20% above market indices and a 14% increase in shipping days. The compa...
- Adjusted EBITDA grew $10M YoY to $25.2M, driven by 34% increase in TCE earnings.
- TCE rates averaged $15,252/day, a 20% premium over market indices for Panamax, Supramax, and Handysize vessels.
- Chartered-in fleet increased 54% YoY, allowing Pangaea to capture market opportunities without compromising flexibility.
- +7 more takeaways
Warner Bros. Discovery Q1 2026 Earnings Call - HBO Max Surpasses 140M Subscribers as Paramount Deal Nears
Warner Bros. Discovery delivered a quarter defined by relentless execution and a clear pivot toward scale. HBO Max crossed 140 million subscribers, driven by aggressive European rollouts and a content...
- HBO Max surpassed 140 million global subscribers in Q1 2026, exceeding guidance and accelerating toward a year-end target of 150 million.
- Streaming profitability has shifted dramatically, with the division moving from a $2 billion annual loss to $1.4 billion in profit last year and accelerating double-digit growth in Q1.
- Content performance is a standout driver, with The Pitt averaging over 20 million viewers per episode and A Knight of the Seven Kingdoms drawing 36 million viewers per episode.
- +7 more takeaways
Acumen Pharmaceuticals Q1 2026 Earnings Call - Sabirnetug ALTITUDE-AD Trial On Track For Late 2026 Readout With $128M Runway Into 2027
Acumen Pharmaceuticals advanced its sabirnetug program through the ALTITUDE-AD Phase II trial, maintaining high conversion rates into the 12-month open-label extension. The company expects top-line ef...
- Acumen Pharmaceuticals ended Q1 2026 with $128.4 million in cash and marketable securities, providing runway into early 2027.
- The ALTITUDE-AD Phase II trial for sabirnetug remains on track, with top-line results expected in late 2026.
- Sabirnetug targets toxic Abeta oligomers rather than amyloid plaques, aiming to differentiate from approved IgG1 antibodies.
- +7 more takeaways
OrganiGram Global Q2 FY2026 Earnings Call - Operational Hiccups in Vapes and IPRs Offset by Sanity Acquisition and Strong Canadian Flower Growth
OrganiGram Global reported a challenging Q2 FY2026, with net revenue declining 9% year-over-year to CAD 59.8 million due to operational execution issues in vapes and infused pre-rolls, alongside a bro...
- Net revenue declined 9% year-over-year to CAD 59.8 million in Q2 FY2026, primarily due to share erosion in vapes and infused pre-rolls caused by internal operational issues.
- The company maintained its position as Canada’s number one licensed producer by market share in Q2, despite a broader recreational market growth slowdown from 5% to 2.2%.
- Operational challenges in infused pre-rolls (IPRs) and vapes led to a 1.6 point share loss in pre-rolls and a 6.1 point year-over-year share decline in vapes, driven by quality inconsistencies and a mismatch in product potency formats.
- +11 more takeaways
Fastly Q1 2026 Earnings Call - Security and Compute Revenue Surge Drives Record Profitability
Fastly delivered a record-breaking first quarter of 2026, with revenue hitting $173 million and growing 20% year-over-year. The company's strategic pivot toward security and edge compute is paying off...
- Revenue reached $173 million, up 20% year-over-year, landing at the high end of guidance.
- Security revenue grew 47% year-over-year, now representing 22% of total revenue.
- Compute revenue surged 67% year-over-year, driven by edge AI workloads and agentic traffic.
- +7 more takeaways
Sea Limited Q1 2026 Earnings Call - E-Commerce and Fintech Scale While Gaming Rebounds
Sea Limited delivered a powerful first quarter of 2026, with total revenue jumping 47% year-over-year to $7.1 billion and adjusted EBITDA crossing the $1 billion mark for the first time. The results h...
- Sea Limited reported Q1 2026 revenue of $7.1 billion, a 47% year-over-year increase, driven by strong performance across all three business segments.
- Adjusted EBITDA surpassed $1 billion for the first time, reflecting improved operational efficiency and scaling of high-margin businesses.
- Shopee’s GMV grew 30% year-over-year, with Brazil emerging as the fastest-growing market and contributing significantly to overall expansion.
- +7 more takeaways
NerdWallet Inc Q1 2026 Earnings Call - Margin Expansion Masks Insurance Volatility and Signals Aggressive Vertical Integration
NerdWallet reported Q1 2026 revenue of $222 million, up 6% year-over-year, with consumer revenue rising 10% to $198 million on strong banking and personal loan demand. SMB revenue fell 15% to $25 mill...
- Total revenue came in at $222 million, up 6% year-over-year, with consumer revenue rising 10% to $198 million and SMB revenue falling 15% to $25 million.
- Non-GAAP operating income reached a record $34 million, beating guidance, driven by lower brand marketing spend and operating leverage on fixed costs.
- Consumer revenue growth was fueled by robust demand for savings accounts and personal loans, partially offset by a decline in credit card revenue due to organic search headwinds.
- +7 more takeaways
Harvard Bioscience Q1 2026 Earnings Call - NPI Revenue Surge Offsets Academic Slowdown
Harvard Bioscience delivered Q1 2026 revenue of $20.8 million, perfectly aligning with guidance despite a year-over-year decline driven by a thawing academic sector in the Americas and APAC distributo...
- Q1 2026 revenue came in at $20.8 million, exactly in line with the $20 million to $22 million guidance range.
- New product innovation (NPI) revenue, led by Mesh MEA, BTX, and SoHo, grew to over 12% of total revenue, up from approximately 4% in Q1 2025.
- Adjusted gross margin expanded 300 basis points year-over-year to 59%, benefiting from cost actions and a higher mix of high-margin NPI products.
- +9 more takeaways
Sanara MedTech Q1 2026 Earnings Call - Pure-Play Surgical Focus Drives First GAAP Profitability
Sanara MedTech delivered its first GAAP profitable quarter as a pure-play surgical company, with Q1 2026 revenue jumping 19% year-over-year to $27.8 million. The company logged $0.4 million in net inc...
- Sanara MedTech achieved its first GAAP net profitability as a pure-play surgical company, reporting $0.4 million in net income or $0.04 per diluted share for Q1 2026, a stark reversal from the $0.6 million loss in Q1 2025.
- Revenue surged 19% year-over-year to $27.8 million, outpacing expectations and driven primarily by increased sales of soft tissue repair products CellerateRX and BIASURGE.
- Gross margins expanded by 100 basis points to 93% of net revenue, reflecting favorable product mix, geographic expansion, and successful penetration into new hospital and ASC networks.
- +7 more takeaways
LightInTheBox Q1 2026 Earnings Call - Record Profit and Branded Apparel Surge Drive Turnaround
LightInTheBox delivered its eighth consecutive profitable quarter and a record first quarter profit of $1.2 million in Q1 2026, up from just $0.1 million in the same period last year. Revenue grew 11%...
- 1. LightInTheBox reported a record first quarter profit of $1.2 million in Q1 2026, a twelvefold increase from the $0.1 million profit in Q1 2025.
- 2. This marks the company’s eighth consecutive profitable quarter, signaling a sustained operational turnaround that began in 2025.
- 3. Total revenue grew 11% year-over-year to $52 million, representing the second consecutive quarter of top-line growth and returning to double-digit expansion.
- +7 more takeaways